Altered NR4A Subfamily Gene Expression Level in Peripheral Blood of Parkinson's and Alzheimer's Disease Patients
| Autor: | Francesca Montarolo, Antonio Bertolotto, Alberto Marchet, Serena Martire, Simona Perga, Daniela Leotta, Désirée Nicole Navone |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Adult Male medicine.medical_specialty Pathology Receptors Steroid Subfamily Neurology Parkinson's disease Central nervous system Gene Expression Biology Toxicology Neuroprotection 03 medical and health sciences 0302 clinical medicine Dopamine Alzheimer Disease Gene expression Nuclear Receptor Subfamily 4 Group A Member 2 medicine Nuclear Receptor Subfamily 4 Group A Member 1 Humans Gene Aged Aged 80 and over Receptors Thyroid Hormone General Neuroscience Gene Expression Profiling Parkinson Disease Middle Aged medicine.disease DNA-Binding Proteins 030104 developmental biology medicine.anatomical_structure Immunology Female 030217 neurology & neurosurgery Biomarkers medicine.drug |
| Zdroj: | Neurotoxicity research. 30(3) |
| ISSN: | 1476-3524 |
| Popis: | Parkinson’s disease (PD) is a neurodegenerative pathology characterized by the degeneration of midbrain dopamine neurons, whose development and maintenance in brain is related to the transcription factor NR4A2 (also called Nurr1). Notably, NR4A2 is a neuroprotective agent with anti-inflammatory role in microglia and astrocytes. Furthermore, mutations in NR4A2 gene are associated to the familial form of PD, and its gene expression level is down-regulated in blood obtained from PD patients. NR4A2 belongs to the NR4A subfamily consisting of three members: NR4A1, NR4A2, and NR4A3. The NR4A subfamily shares high degree of homology in their molecular structure and cooperates in a spectrum of functions ranging from central nervous system to immune control during physiological and pathological conditions. Considering the close functional link between the member of NR4A subfamily, we performed a gene expression analysis of NR4A1, NR4A2, and NR4A3 in peripheral blood obtained from PD patients and healthy controls (HC). Then, in order to evaluate possible involvement of the NR4A subfamily in other neurodegenerative processes, we carried out the same analysis on blood obtained from Alzheimer’s disease (AD) patients. A correlation between clinical features and gene expression was also evaluated. We found a marked down-regulated gene expression of the NR4A subfamily obtained from PD patients, but only a NR4A1 decrease in AD patients compared to HC. This study reports that the entire NR4A subfamily and not only NR4A2 could be systemically involved in PD suggesting that the study of these factors could be a promising approach to develop PD therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|